AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
New HIV/AIDS research from J. Berenguer et al outlined
November 3rd, 2008
"The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials. We conducted an open-label, randomized study to compare the noninferiority of ddI/3TC/EFV with the lamivudine- zidovudine tablet and EFV (COM/EFV), both administered with food to improve tolerability and convenience," scientists in Madrid, Spain report. "Patients were stratified by HIV-1 RNA level of <5.0 log(10) or >= 5.0 log(10) copies/mL. The primary end point was the percentage of patients with an HIV-1 RNA level of <50 copies/mL at week 48, determined...
Source: AIDS Weekly (2008-11-03)
|
